CTOs on the Move

XenoPort

www.xenoport.com

 
XenoPort, Inc. is a Santa Clara, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.xenoport.com
  • 3410 Central Expy
    Santa Clara, CA USA 95051
  • Phone: 408.616.7200

Executives

Name Title Contact Details

Similar Companies

AgBiome

AgBiome® partners with the microbial world to improve our planet. AgBiome discovers and develops innovative biological and trait products for crop protection. The proprietary GENESIS™ discovery platform efficiently captures diverse, unique microbes for agriculturally relevant applications, and screens them with industry-best assays for insect, disease, and nematode control. Through its commercial subsidiary, AgBiome develops and sells proprietary crop protection solutions. The first of these, Howler®, is a revolutionary fungicide for disease control in a broad variety of crops.

GenBio

ormed in 1994, GenBio is an experienced, fully integrated medical diagnostic company focused on infectious disease and autoimmune disease diagnostics. GenBio develops, manufactures and markets extensive lines of infectious disease and autoimmunity

Anagenex

Discovering new medicines by combining ultra throughput biochemistry and machine learning.

Bioporto

BioPorto s flagship product, The NGAL Test™, aids in the risk assessment of AKI in critically ill patients. CE marked for IVD use in select regions.

Aruvant

Aruvant`s mission is to bring hope to patients living with rare diseases by developing life changing and potentially curative gene therapies, with a near-term focus on sickle cell disease. Aruvant is a part of the Roivant family of companies. We have a talented team with extensive experience in the development, manufacturing and commercialization of gene therapy products. We have an active research program with a lead product candidate in development for individuals suffering from sickle cell disease (SCD). Our lead product candidate, ARU-1801, an investigational lentiviral gene therapy, is currently in a clinical trial as a potential one-time curative treatment for SCD. Preliminary clinical data from the ongoing Phase 1/2 study demonstrated durable efficacy in reducing the negative impacts of SCD. We are preparing for the launch of our pivotal clinical trial in SCD. We continue to look for new people to add to our talented team.